After the publication of these phase 3 trials, further publication of subgroup analyses, including by age, risk factors for bleeding, degree of renal function and concomitant antiplatelet therapy will help identify the optimal niche for FXI/XIa inhibitors in treating patients with AF. This evidence concerns the gene F11 and atrial fibrillation.